|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
70,650,000 |
Market
Cap: |
3.62(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.62 - $89.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
89,721 |
159,721 |
184,721 |
409,721 |
Total Sell Value |
$6,558,882 |
$10,834,513 |
$12,456,407 |
$25,314,056 |
Total People Sold |
3 |
3 |
3 |
3 |
Total Sell Transactions |
10 |
12 |
13 |
22 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Klein Lawrence Otto |
CBO & COO |
|
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,584 |
26,909 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,834 |
290,919 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,834 |
46,539 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-12-20 |
4 |
OE |
$1.81 |
$32,128 |
D/D |
17,750 |
279,085 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-12-06 |
4 |
D |
$69.17 |
$2,615,871 |
D/D |
(37,818) |
261,335 |
|
- |
|
Ho Tony W |
Executive VP, Head of R&D |
|
2021-12-06 |
4 |
D |
$69.17 |
$872,026 |
D/D |
(12,607) |
52,364 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2021-12-06 |
4 |
D |
$69.17 |
$435,979 |
D/D |
(6,303) |
43,542 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2021-12-06 |
4 |
D |
$69.17 |
$773,666 |
D/D |
(11,185) |
22,325 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-12-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
80,000 |
299,153 |
|
- |
|
Ho Tony W |
Executive VP, Head of R&D |
|
2021-12-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,667 |
64,971 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2021-12-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,333 |
49,845 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2021-12-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,667 |
33,510 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2021-12-02 |
4 |
OE |
$13.62 |
$99,998 |
D/D |
7,342 |
36,512 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-12-01 |
4 |
D |
$75.10 |
$58,503 |
D/D |
(779) |
219,153 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-10-15 |
4 |
OE |
$1.81 |
$59,730 |
D/D |
33,000 |
219,932 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2021-09-13 |
4 |
D |
$117.86 |
$495,837 |
D/D |
(4,207) |
6,843 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2021-09-13 |
4 |
D |
$117.86 |
$558,774 |
D/D |
(4,741) |
29,170 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2021-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
11,050 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2021-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
33,911 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-09-01 |
4 |
D |
$124.83 |
$98,241 |
D/D |
(787) |
186,932 |
|
- |
|
Tomsicek Michael John |
Chief Financial Officer |
|
2021-08-06 |
4 |
AS |
$138.22 |
$3,462,926 |
D/D |
(25,000) |
1,891 |
|
-42% |
|
Tomsicek Michael John |
Chief Financial Officer |
|
2021-08-06 |
4 |
OE |
$17.75 |
$443,750 |
D/D |
25,000 |
26,891 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-08-05 |
4 |
AS |
$126.67 |
$3,675,939 |
D/D |
(28,500) |
187,719 |
|
-44% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-08-05 |
4 |
OE |
$12.57 |
$358,245 |
D/D |
28,500 |
216,219 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-08-04 |
4 |
AS |
$125.02 |
$187,530 |
D/D |
(1,500) |
187,719 |
|
-41% |
|
483 Records found
|
|
Page 4 of 20 |
|
|